[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chengdu Jinjiang Maternity and Child Health Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":145},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,65,94,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100631479","intranasal-dexmedetomidine-for-prevention-of-intrapartum-fever-100631479",false,"NCT07501221","Intranasal Dexmedetomidine for Prevention of Intrapartum Fever","Intranasal Dexmedetomidine and Labor Analgesia-Related Intrapartum Fever: A Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA physical status II or III\n* Age ≥ 18 years\n* Singleton pregnancy, cephalic presentation\n* No contraindications to neuraxial anesthesia and voluntarily requesting labor analgesia\n\nExclusion Criteria:\n\n* Maternal temperature ≥ 37.3°C before labor analgesia\n* Allergy to α2-adrenergic receptor agonists\n* Severe pregnancy complications or systemic diseases\n* Use of analgesics, nonsteroidal anti-inflammatory drugs, or other medications that may affect body temperature within one week prior to enrollment\n* Heart rate \\\u003C 60 bpm or systolic blood pressure \\\u003C 90 mmHg before labor analgesia\n* Severe rhinitis or nasal deformity\n* Premature rupture of membranes","FEMALE","18 Years",{"count":19,"type":20},446,"ESTIMATED","INTERVENTIONAL",[23],"NA","Brief Title: Intranasal Dexmedetomidine for Prevention of Intrapartum Fever This study aims to evaluate the effect of intranasal dexmedetomidine (Dex) administered before neuraxial labor analgesia on the incidence of intrapartum fever in women undergoing vaginal delivery.\n\nThis prospective, randomized, double-blind, placebo-controlled trial will enroll 446 parturients scheduled for vaginal delivery with neuraxial labor analgesia at Chengdu Jinjiang Maternal and Child Health Hospital from 2026 to 2027. Participants will be randomly assigned in a 1:1 ratio to receive either intranasal Dex (50 μg) or an equal volume of normal saline before the initiation of labor analgesia.\n\nPrimary Outcome Measure:\n\nIncidence of intrapartum fever (temperature ≥ 38.0℃) from initiation of labor analgesia to 2 hours postpartum\n\nSecondary Outcome Measures:\n\nTemperature-related outcomes: Incidence of fever at thresholds of ≥ 37.5℃ and ≥ 38.5℃; hourly temperature trends assessed by continuous wireless axillary monitoring Analgesic effect: NRS pain scores before labor analgesia and at 30 minutes, 1 hour, and 3 hours after analgesia Sedative effect: Ramsay Sedation Scale scores at the same time points Maternal safety: Incidence of bradycardia (heart rate \\\u003C 60 bpm), hypotension (systolic blood pressure \\\u003C 90 mmHg or \\\u003C 20% of baseline), nausea, vomiting, oversedation (Ramsay ≥ 4), and respiratory depression (SpO₂ \\\u003C 90%) Labor characteristics: Duration of first, second, and third stages of labor, total labor duration, and duration of labor analgesia Delivery outcomes: Mode of delivery (spontaneous vaginal delivery or cesarean section) and total consumption of local anesthetics Neonatal outcomes: Apgar scores at 1, 5, and 10 minutes, and NICU admission rate We hypothesize that intranasal Dex administered before labor analgesia will significantly reduce the incidence of intrapartum fever compared to placebo. This study is expected to provide a novel, non-invasive, and effective strategy for preventing epidural-related maternal fever, thereby improving maternal safety and perinatal outcomes in women undergoing vaginal delivery.",[26],"Intrapartum Fever",[28,26,29],"labor analgesia","Dexmedetomidine","NOT_YET_RECRUITING","2026-03-26",{"date":33,"type":34},"2026-03-30","ACTUAL",{"date":36,"type":20},"2026-05-01",{"date":38,"type":20},"2027-10-01",{"name":40,"class":41},"Chengdu Jinjiang Maternity and Child Health Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100631518","intranasal-dexmedetomidine-for-postpartum-depression-prevention-100631518","NCT07501728","Intranasal Dexmedetomidine for Postpartum Depression Prevention","Intranasal Dexmedetomidine for Prevention of Postpartum Depression in Women Receiving Combined Spinal-Epidural Labor Analgesia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA physical status II or III.\n* Age ≥ 18 years.\n* Singleton pregnancy, cephalic presentation\n* No contraindications to neuraxial anesthesia and voluntarily requesting labor analgesia for planned vaginal delivery\n\nExclusion Criteria:\n\n* History of bipolar disorder, psychiatric disorders, or suicidal ideation\n* Severe cardiac, cerebral, hepatic, or renal disease\n* Allergy to α2-adrenergic receptor agonists\n* Baseline bradycardia (heart rate \\\u003C 60 bpm) or cardiac conduction abnormalities before labor analgesia\n* Hypotension (systolic blood pressure \\\u003C 90 mmHg) before labor analgesia\n* History of drug or alcohol abuse\n* Severe rhinitis or nasal cavity deformity",{"count":51,"type":20},270,[23],"Brief Title: Intranasal Dexmedetomidine for Postpartum Depression Prevention: A Randomized Trial This study aims to evaluate the effect of intranasal dexmedetomidine (Dex) administered before combined spinal-epidural labor analgesia on the incidence of postpartum depression (PPD) in women undergoing vaginal delivery. This prospective, randomized, double-blind, placebo-controlled trial will enroll 270 parturients scheduled for vaginal delivery with neuraxial labor analgesia at Chengdu Jinjiang Maternal and Child Health Hospital from 2026 to 2027. Participants will be randomly assigned in a 1:1 ratio to receive either intranasal Dex (50 μg) or an equal volume of normal saline before the initiation of labor analgesia.\n\nPrimary Outcome Measure:\n\nIncidence of PPD at 42 days postpartum, defined as an Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10\n\nSecondary Outcome Measures:\n\nIncidence of PPD at 7 days postpartum (EPDS ≥ 10) Sleep quality assessed by Numerical Rating Scale (NRS) and incidence of sleep disturbance (NRS ≥ 6) at 7 and 42 days postpartum Analgesic effect: NRS pain scores before labor analgesia and at 30 minutes, 1 hour, and 3 hours after analgesia Sedative effect: Ramsay Sedation Scale scores at the same time points Adverse events: bradycardia, hypotension, nausea\u002Fvomiting, respiratory depression, oversedation, intrapartum fever Labor characteristics: duration of first, second, and third stages of labor, and total labor duration Duration of labor analgesia Mode of delivery: spontaneous vaginal delivery or cesarean section Neonatal outcomes: Apgar scores at 1, 5, and 10 minutes, and NICU admission rate We hypothesize that intranasal Dex administered before labor analgesia will significantly reduce the incidence of PPD at 42 days postpartum compared to placebo. This study is expected to provide a novel, non-invasive, and effective strategy for PPD prevention in women undergoing vaginal delivery, thereby improving maternal mental health and neonatal outcomes.",[55],"Postpartum Depression (PPD)",[57,29,58],"Postpartum Depression","Labor Analgesia","2026-03-24",{"date":33,"type":34},{"date":36,"type":20},{"date":63,"type":20},"2027-04-01",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100620123","predicting-hypothermia-in-gynecological-laparoscopic-surgery-using-machine-learning-100620123","NCT07353528","Predicting Hypothermia in Gynecological Laparoscopic Surgery Using Machine Learning","Development and Validation of a Machine Learning Model to Predict Hypothermia in Gynecological Laparoscopic Surgery Based on Preoperative Clinical Indicators: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Patients scheduled for laparoscopic surgery.\n\nExclusion Criteria:\n\n* Preoperative body temperature exceeding 37.5°C or below 36.0°C.\n* History of hypothyroidism or hyperthyroidism.\n* Patients with thermoregulatory dysfunction, such as severe infection or central nervous system disorders.\n* Patients who refuse to sign the informed consent form.",{"count":73,"type":20},1000,"OBSERVATIONAL","Brief Title: Predicting Hypothermia in Gynecological Laparoscopic Surgery Using Machine Learning\n\nBrief Summary: This study aims to develop and validate a machine learning model for predicting intraoperative hypothermia (IOH) in patients undergoing gynecological laparoscopic surgery based on preoperative clinical indicators. This prospective, multicenter case-control study will enroll female patients aged 18 years and older who are scheduled for laparoscopic surgery across multiple hospitals from 2026 to 2027. The primary objective is to identify high-risk patients who may experience IOH, defined as a core temperature below 36.0°C during surgery.\n\nParticipants will be classified into two groups: the IOH group, consisting of patients who experience hypothermia, and the normal temperature group, comprising patients who maintain a core temperature of 36.0°C or higher. Data collection will include demographics, comorbidities, surgical details, anesthesia information, and preoperative laboratory results.\n\nThe primary outcome measure will be the area under the curve (AUC) of the model, assessing its predictive performance at various thresholds. Secondary outcomes will include sensitivity, positive predictive value, negative predictive value, and F1 score. The study hypothesizes that the developed machine learning model will significantly improve the accuracy and timeliness of predicting IOH, thereby enhancing patient safety during surgery and postoperative recovery. This research is expected to inform clinical practices related to preventative warming strategies, ultimately improving patient outcomes in gynecological laparoscopic surgery.",[77,78,79],"Laparoscopic Surgery","Intraoperative Hypothermia","Gynecological Surgery",[81,82,83,84],"Laparoscopic surgery","Intraoperative hypothermia","Machine learning","Gynecology","2026-01-18",{"date":87,"type":34},"2026-01-20",{"date":89,"type":20},"2026-03-01",{"date":91,"type":20},"2026-07-01",{"name":40,"class":41},4,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100593697","nalbuphine-dosing-and-its-impact-on-anxiety-and-depression-in-ectopic-pregnancy-surgery-100593697","NCT07009808","Nalbuphine Dosing and Its Impact on Anxiety and Depression in Ectopic Pregnancy Surgery","Effects of Different Doses of Nalbuphine on Anxiety and Depression in Patients Undergoing Ectopic Pregnancy Surgery: A Prospective, Randomized, Controlled Study","Inclusion Criteria:\n\n1. Confirmed diagnosis of ectopic pregnancy, aged ≥18 years, and with normal psychological status.\n2. Patients planned to undergo single-port laparoscopic surgery under general anesthesia, followed by postoperative patient-controlled intravenous analgesia (PCIA).\n3. Patients classified as ASA I or II.\n4. Able to understand the study process and methods, voluntarily participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients using other analgesic methods or multiple analgesic approaches.\n2. Patients with a history of allergies or allergies to anesthetic drugs.\n3. Patients with a history of depression or mental illness.\n4. Patients with other severe organ dysfunction.\n5. Patients unable to operate the intravenous analgesia pump independently.",{"count":102,"type":20},165,[23],"This prospective, randomized, controlled study aims to evaluate the impact of different doses of nalbuphine on anxiety and depression in patients undergoing surgery for ectopic pregnancy. Ectopic pregnancy, which occurs in approximately 2% of all pregnancies, often requires surgical intervention, leading to potential psychological distress such as anxiety and depression in affected women. Effective postoperative pain management is essential to enhance recovery and reduce emotional disturbances.\n\nThe study will involve 165 eligible patients diagnosed with ectopic pregnancy at Jinjiang District Maternal and Child Health Hospital. Participants will be randomly assigned to three groups, each receiving a different concentration of nalbuphine combined with metoclopramide for postoperative analgesia. The primary outcome will focus on changes in anxiety and depression scores measured on postoperative day three, while secondary outcomes will assess pain levels, the use of patient-controlled analgesia (PCA), the necessity for rescue analgesics, and the occurrence of adverse reactions.\n\nSample size calculations suggest that at least 165 participants are required to achieve adequate statistical power. Data will be analyzed using SPSS 25.0 software, with results expected to provide insights into the effectiveness of nalbuphine in improving postoperative recovery and mental health in women experiencing ectopic pregnancy. The study has received ethical approval and is funded by the Chengdu Medical Research Projects (No. 2023465, 2022548, and 2023304).",[106,107,108,109],"Ectopic Pregnancy","Anxiety","Depression","Nalbuphine",[106,107,108,109],"2025-06-06",{"date":113,"type":34},"2025-06-08",{"date":115,"type":20},"2025-06-20",{"date":117,"type":20},"2025-10-30",{"name":40,"class":41},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":42},"100593531","effects-of-ropivacaine-concentrations-on-prolonged-labor-analgesia-100593531","NCT07007650","Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia","Effects of Different Concentrations of Ropivacaine on Prolonged Labor Analgesia","Inclusion Criteria:\n\n1. ASA II\n2. Age ≥ 18 years\n3. Singleton pregnancy\n4. No contraindications for epidural puncture and voluntarily accepting labor analgesia\n5. Maternal participants changing the first pump fluid\n\nExclusion Criteria:\n\n1. Contraindications for epidural labor analgesia\n2. Serious heart, brain, liver, or kidney diseases\n3. Mental abnormalities\n4. Neurological diseases\n5. Maternal request for management of breakthrough pain before changing the pump fluid",{"count":127,"type":20},100,[23],"With the changes in medical models and improvements in people's quality of life, parturients have higher demands for childbirth, making the alleviation and elimination of labor pain an important aspect of modern obstetrics. Intrathecal labor analgesia has been widely adopted in clinical practice to relieve pain. However, current studies mainly focus on parturients who are just beginning to receive labor analgesia, while for those experiencing prolonged analgesia, medical institutions still use traditional formulations, lacking relevant guidelines or expert consensus. In such cases, prolonged waiting and anxiety may lower the pain tolerance of parturients, leading to an increased need for higher concentrations of local anesthetics. To address this clinical gap, this study aims to explore the effects of different concentrations of ropivacaine in prolonged labor analgesia and has designed a prospective randomized controlled trial (RCT) to provide evidence for improving the analgesic regimen for this group of parturients.",[58,131,132,133],"Prolonged","Ropivacaine","Concentration",[58,135,136,137],"Ropivacaine Concentration","Prolonged Pain","Maternal-Neonatal Safety","2025-06-05",{"date":111,"type":34},{"date":141,"type":20},"2025-06-14",{"date":143,"type":20},"2025-09-10",{"name":40,"class":41},""]